Pricing

Five things for pharma marketers to know: Wednesday, June 21, 2017

Five things for pharma marketers to know: Wednesday, June 21, 2017

By

Insurance companies balk at expensive PCSK9 inhibitors; Publicis to focus investments on AI platform; clinical trial reveals Novartis' eye drug requires less frequent injections

Five things for pharma marketers to know: Friday, June 16, 2017

Five things for pharma marketers to know: Friday, June 16, 2017

By

Apple reportedly working to bring EMRs to iPhone; FDA to study disclosures in ads; Trump admin discussing drug price EO

Five things for pharma marketers to know: Friday, June 9, 2017

Five things for pharma marketers to know: Friday, June 9, 2017

By

The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision

Physicians call for DTC ads to include retail prices

Physicians call for DTC ads to include retail prices

By

They are asking the American Medical Association to support the policy proposal.

Five things for pharma marketers to know: Monday, June 5, 2017

Five things for pharma marketers to know: Monday, June 5, 2017

By

Medicare beneficiaries struggle to pay for COPD inhalers; Novartis partners with IBM Watson Health; Mylan hasn't lowered EpiPen prices

Five things for pharma marketers to know: Thursday, June 1, 2017

Five things for pharma marketers to know: Thursday, June 1, 2017

By

50% of consumers say they will share their health data with tech giants; pharma CEOs expect pricing proposal from Trump administration; FDA approves generic versions of Strattera

Keep Calm and Sell Drugs: Your New Daily Affirmation?

Keep Calm and Sell Drugs: Your New Daily Affirmation?

By

To be sure, anything borrowing from the well-known "Keep Calm" genre should not be construed as advice. The doctor is definitely not in.

In Surprising Twist, Trust Rises for Healthcare Companies

In Surprising Twist, Trust Rises for Healthcare Companies

But will pharma and biotechnology firms be able to advance this year's positive momentum?

Five things for pharma marketers to know: Tuesday, May 9, 2017

Five things for pharma marketers to know: Tuesday, May 9, 2017

By

Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials

Five things for pharma marketers to know: Monday, May 8, 2017

Five things for pharma marketers to know: Monday, May 8, 2017

By

Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions

Five things for pharma marketers to know: Thursday, May 4, 2017

Five things for pharma marketers to know: Thursday, May 4, 2017

By

Louisiana may use 1910 law to discount hep-C drugs; House bill would reduce coverage for 24 million people; drugmakers pursue pay-for-performance deals

U.S. drug spend grew by 6% in 2016, the lowest rate in two years

U.S. drug spend grew by 6% in 2016, the lowest rate in two years

By

This is likely due to fewer product launches and lower price increases.

Five things for pharma marketers to know: Wednesday, May, 3, 2017

Five things for pharma marketers to know: Wednesday, May, 3, 2017

By

Teaching hospitals that limit detailing prescribe fewer branded drugs; new ad campaign criticizes drug pricing; Ad Age reports healthcare is fastest growing agency discipline

Pharma Execs Can Do More to Address Industry's Reputation

Pharma Execs Can Do More to Address Industry's Reputation

Some leaders have stepped up, and this serves their companies - and the industry - well.

Five things for pharma marketers to know: Thursday, April 20, 2017

Five things for pharma marketers to know: Thursday, April 20, 2017

By

Tesaro discloses price for new drug that differs from FDA-approved dosage; uniQure discontinues Glybera; O'Reilly leaves Fox

Five things for pharma marketers to know: Tuesday, April 11, 2017

Five things for pharma marketers to know: Tuesday, April 11, 2017

By

Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer

Five things for pharma marketers to know: Friday, March 17, 2017

Five things for pharma marketers to know: Friday, March 17, 2017

By

The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug

Five things for pharma marketers to know: Thursday, March 16, 2017

Five things for pharma marketers to know: Thursday, March 16, 2017

By

Marathon to sell Emflaza to PTC Therapeutics; Emma Walmsley's salary is lower than Andrew Witty's; Trump considers Medicare negotiation of drug prices

Five things for pharma marketers to know: Tuesday, March 14, 2017

Five things for pharma marketers to know: Tuesday, March 14, 2017

By

Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices

Five things for pharma marketers to know: Wednesday, March 8, 2017

Five things for pharma marketers to know: Wednesday, March 8, 2017

By

Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs

Five things for pharma marketers to know: Monday, March 6, 2017

Five things for pharma marketers to know: Monday, March 6, 2017

By

Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema

Five things for pharma marketers to know: Thursday, March 2, 2017

Five things for pharma marketers to know: Thursday, March 2, 2017

By

Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project

Five things for pharma marketers to know: Wednesday, March 1, 2017

Five things for pharma marketers to know: Wednesday, March 1, 2017

By

Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported

Five things for pharma marketers to know: Tuesday, February 28, 2017

Five things for pharma marketers to know: Tuesday, February 28, 2017

By

J&J discloses list prices for its drugs; Kite's CAR-T therapy meets study goals; healthcare providers seek to engage patients in decisionmaking

Top 25 rare disease brands, by sales

Top 25 rare disease brands, by sales

Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

By

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

By

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Five things for pharma marketers to know: Monday, February 6, 2017

Five things for pharma marketers to know: Monday, February 6, 2017

By

Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year

It's Time for Trump to Make Good on his Drug Pricing Promises

It's Time for Trump to Make Good on his Drug Pricing Promises

Last week President Trump told drugmakers that 'the pricing has been astronomical.'

MM&M's top 5 stories in January 2017

MM&M's top 5 stories in January 2017

By

Merck and Aetna partner in value-based drug pricing; data scientists rising in the biopharma ranks; Japanese pharma leads digital health innovation